GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines
- Conditions
- Influenza, Human
- Interventions
- Other: Vaccine safety surveillance
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 19334
- Registration Number
- NCT02893878
- Locations
- π¬π§
GSK Investigational Site, Surrey, United Kingdom
Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 477
- Registration Number
- NCT02889809
- Locations
- πΏπ¦
GSK Investigational Site, Cape Town, South Africa
Prevalence, Strain Circulation and Disease Burden Study of Seasonal Influenza A and B in Panama, Selected Countries of Central America and the Caribbean From the Year 2010 to 2015
- Conditions
- Influenza, Human
- Interventions
- Other: Data collection
- First Posted Date
- 2016-08-31
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1839
- Registration Number
- NCT02885246
- Locations
- π΅π¦
GSK Investigational Site, Panama, Panama
Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT02880852
- Locations
- π¨π³
GSK Investigational Site, Suzhou, China
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
- Conditions
- AnaemiaAspergillosis, Allergic Bronchopulmonary
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2964
- Registration Number
- NCT02879305
- Locations
- π¬π§
GSK Investigational Site, Salford, United Kingdom
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
- Conditions
- Anaemia
- Interventions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3872
- Registration Number
- NCT02876835
- Locations
- π»π³
GSK Investigational Site, Ho Chi Minh, Vietnam
Asthma Control Test Guided Treatment in Chinese Subjects
- Conditions
- Asthma
- Interventions
- Drug: ACT guided Routine TreatmentDrug: Routine Treatment
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 530
- Registration Number
- NCT02868281
- Locations
- π¨π³
GSK Investigational Site, Shanghai, China
Assessment of the Efficacy of an Experimental Occlusion Technology Dentifrice in Dentinal Hypersensitivity
- Conditions
- Dentin Sensitivity
- Interventions
- Other: Sodium monofluorophosphate (SMFP)Other: Stannous fluoride (SnF2)
- First Posted Date
- 2016-08-10
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 135
- Registration Number
- NCT02861664
- Locations
- π¨π³
GSK Investigational Site, Wuhan, China
Motivation, Brain Function and Mood in Individuals With Cold and/or Flu
- Conditions
- Cognition
- Interventions
- Behavioral: Participants self-administered questionnaire and assessment
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 114
- Registration Number
- NCT02860169
- Locations
- π¬π§
GSK Investigational Site, Brentford, Middlesex, United Kingdom
Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: GSK2982772 60 mgDrug: Placebo
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 52
- Registration Number
- NCT02858492
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom